AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells
Open Access
- 1 March 2007
- journal article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 21 (5), 877-885
- https://doi.org/10.1038/sj.leu.2404614
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Nuclear factor-κB in cancer development and progressionNature, 2006
- Drug therapy for acute myeloid leukemiaBlood, 2005
- FLT3 Tyrosine Kinase InhibitorsInternational Journal of Hematology, 2005
- Targeting NF- B activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cellsBlood, 2005
- FLT3: ITDoes matter in leukemiaLeukemia, 2003
- The role of FLT3 in haematopoietic malignanciesNature Reviews Cancer, 2003
- Role of FLT3 in leukemiaCurrent Opinion in Hematology, 2002
- Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cellsBlood, 2001
- Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformationLeukemia, 2000
- Aberrant rel/nfkb genes and activity in human cancerOncogene, 1999